aquilant endoscopy limited
aquilant endoscopy limited Company Information
Company Number
03402556
Website
www.aquilantservices.comRegistered Address
aquilant house, unit b1-b2 bond close, basingstoke, RG24 8PZ
Industry
Retail sale of medical and orthopaedic goods (other than hearing aids) n.e.c., in specialised stores
Telephone
01256306506
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
healthcare acquisition limited 100%
aquilant endoscopy limited Estimated Valuation
Pomanda estimates the enterprise value of AQUILANT ENDOSCOPY LIMITED at £3.7m based on a Turnover of £11.8m and 0.32x industry multiple (adjusted for size and gross margin).
aquilant endoscopy limited Estimated Valuation
Pomanda estimates the enterprise value of AQUILANT ENDOSCOPY LIMITED at £4.2m based on an EBITDA of £952k and a 4.46x industry multiple (adjusted for size and gross margin).
aquilant endoscopy limited Estimated Valuation
Pomanda estimates the enterprise value of AQUILANT ENDOSCOPY LIMITED at £16.7m based on Net Assets of £6.8m and 2.47x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Aquilant Endoscopy Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Aquilant Endoscopy Limited Overview
Aquilant Endoscopy Limited is a live company located in basingstoke, RG24 8PZ with a Companies House number of 03402556. It operates in the retail sale of medical and orthopaedic goods in specialised stores (not incl. hearing aids) n.e.c. sector, SIC Code 47749. Founded in July 1997, it's largest shareholder is healthcare acquisition limited with a 100% stake. Aquilant Endoscopy Limited is a mature, mid sized company, Pomanda has estimated its turnover at £11.8m with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Aquilant Endoscopy Limited Health Check
Pomanda's financial health check has awarded Aquilant Endoscopy Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 1 areas for improvement. Company Health Check FAQs
2 Strong
9 Regular
1 Weak
Size
annual sales of £11.8m, make it in line with the average company (£11.1m)
£11.8m - Aquilant Endoscopy Limited
£11.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 4%, show it is growing at a similar rate (4.2%)
4% - Aquilant Endoscopy Limited
4.2% - Industry AVG
Production
with a gross margin of 35.7%, this company has a comparable cost of product (40.7%)
35.7% - Aquilant Endoscopy Limited
40.7% - Industry AVG
Profitability
an operating margin of 5% make it as profitable than the average company (5.3%)
5% - Aquilant Endoscopy Limited
5.3% - Industry AVG
Employees
with 30 employees, this is similar to the industry average (30)
30 - Aquilant Endoscopy Limited
30 - Industry AVG
Pay Structure
on an average salary of £54.7k, the company has an equivalent pay structure (£51.6k)
£54.7k - Aquilant Endoscopy Limited
£51.6k - Industry AVG
Efficiency
resulting in sales per employee of £392.2k, this is more efficient (£258.1k)
£392.2k - Aquilant Endoscopy Limited
£258.1k - Industry AVG
Debtor Days
it gets paid by customers after 56 days, this is near the average (56 days)
56 days - Aquilant Endoscopy Limited
56 days - Industry AVG
Creditor Days
its suppliers are paid after 55 days, this is slower than average (27 days)
55 days - Aquilant Endoscopy Limited
27 days - Industry AVG
Stock Days
it holds stock equivalent to 54 days, this is in line with average (54 days)
54 days - Aquilant Endoscopy Limited
54 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (20 weeks)
0 weeks - Aquilant Endoscopy Limited
20 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 55.9%, this is a similar level of debt than the average (52.9%)
55.9% - Aquilant Endoscopy Limited
52.9% - Industry AVG
aquilant endoscopy limited Credit Report and Business Information
Aquilant Endoscopy Limited Competitor Analysis
Perform a competitor analysis for aquilant endoscopy limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
aquilant endoscopy limited Ownership
AQUILANT ENDOSCOPY LIMITED group structure
Aquilant Endoscopy Limited has no subsidiary companies.
Ultimate parent company
ADDLIFE AB
#0133717
HEALTHCARE ACQUISITION LIMITED
IE630286
2 parents
AQUILANT ENDOSCOPY LIMITED
03402556
aquilant endoscopy limited directors
Aquilant Endoscopy Limited currently has 2 directors. The longest serving directors include Mr Nathan Pettitt (Dec 2022) and Mr David Boland (Apr 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Nathan Pettitt | 52 years | Dec 2022 | - | Director | |
| Mr David Boland | England | 40 years | Apr 2023 | - | Director |
AQUILANT ENDOSCOPY LIMITED financials
Aquilant Endoscopy Limited's latest turnover from December 2022 is £11.8 million and the company has net assets of £6.8 million. According to their latest financial statements, Aquilant Endoscopy Limited has 30 employees and maintains cash reserves of £150 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 11,765,000 | 10,313,000 | 10,097,000 | 10,603,103 | 8,129,872 | 8,532,456 | 8,548,971 | 8,970,906 | 7,604,972 | 10,320,577 | 9,104,079 | 7,153,825 | 6,674,176 | 6,775,153 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 7,566,000 | 7,019,000 | 5,281,000 | 6,901,496 | 4,951,650 | 4,587,916 | 4,502,859 | 4,893,871 | 4,160,448 | 5,805,824 | 4,904,490 | 4,044,175 | 4,200,168 | 4,055,925 |
| Gross Profit | 4,199,000 | 3,294,000 | 4,816,000 | 3,701,607 | 3,178,222 | 3,944,540 | 4,046,112 | 4,077,035 | 3,444,524 | 4,514,753 | 4,199,589 | 3,109,650 | 2,474,008 | 2,719,228 |
| Admin Expenses | 3,616,000 | 2,774,000 | 1,951,000 | 2,992,001 | 3,031,453 | 2,720,613 | ||||||||
| Operating Profit | 583,000 | 520,000 | 2,865,000 | 709,606 | -557,445 | -1,385 | ||||||||
| Interest Payable | 3,000 | 2,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,596 | 1,567 |
| Interest Receivable | 1,000 | 0 | 1,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | 581,000 | 518,000 | 2,866,000 | 709,606 | 342,710 | 876,053 | 772,604 | 880,608 | 445,047 | 853,991 | 747,202 | -225,281 | -560,041 | -2,952 |
| Tax | -122,000 | -99,000 | -567,000 | -185,470 | -881 | -175,036 | -177,815 | -179,891 | -100,523 | -179,706 | -196,661 | 50,182 | 123,908 | 64,480 |
| Profit After Tax | 459,000 | 419,000 | 2,299,000 | 524,136 | 341,829 | 701,017 | 594,789 | 700,717 | 344,524 | 674,285 | 550,541 | -175,099 | -436,133 | 61,528 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 500,000 | 2,850,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 459,000 | 419,000 | 2,299,000 | 524,136 | 341,829 | 201,017 | -2,255,211 | 700,717 | 344,524 | 674,285 | 550,541 | -175,099 | -436,133 | 61,528 |
| Employee Costs | 1,640,000 | 1,501,000 | 1,450,000 | 1,742,242 | 1,311,878 | 1,411,417 | 1,420,954 | 1,322,944 | 1,375,318 | 1,467,442 | 1,329,175 | 1,189,907 | 1,242,127 | 1,211,228 |
| Number Of Employees | 30 | 29 | 29 | 29 | 27 | 29 | 30 | 30 | 29 | 30 | 29 | 29 | 34 | 31 |
| EBITDA* | 952,000 | 680,000 | 2,865,000 | 1,370,291 | -66,886 | 484,126 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 587,000 | 375,000 | 281,000 | 220,702 | 617,979 | 783,272 | 599,747 | 805,373 | 1,122,039 | 1,297,896 | 1,143,322 | 1,167,823 | 1,312,656 | 1,638,067 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 587,000 | 375,000 | 281,000 | 220,702 | 617,979 | 783,272 | 599,747 | 805,373 | 1,122,039 | 1,297,896 | 1,143,322 | 1,167,823 | 1,312,656 | 1,638,067 |
| Stock & work in progress | 1,138,000 | 858,000 | 697,000 | 892,541 | 913,493 | 1,836,676 | 2,276,994 | 2,180,901 | 3,392,810 | 3,138,021 | 3,889,712 | 4,609,219 | 4,091,422 | 3,393,071 |
| Trade Debtors | 1,813,000 | 584,000 | 313,000 | 1,322,922 | 1,040,882 | 751,929 | 2,196,303 | 1,334,555 | 1,878,137 | 1,787,037 | 1,025,809 | 2,329,754 | 1,958,877 | 1,241,632 |
| Group Debtors | 11,233,000 | 8,510,000 | 7,421,000 | 4,308,091 | 3,957,427 | 4,413,440 | 2,308,007 | 2,861,476 | 2,535,692 | 2,101,087 | 1,458,795 | 0 | 702,163 | 761,831 |
| Misc Debtors | 423,000 | 649,000 | 145,000 | 322,121 | 301,143 | 260,890 | 258,690 | 310,269 | 243,425 | 223,026 | 144,658 | 230,663 | 564,632 | 346,714 |
| Cash | 150,000 | 226,000 | 233,000 | 273,743 | 217,777 | 1,549,997 | 2,392,940 | 3,219,423 | 1,169,499 | 834,545 | 584,861 | 572,008 | 270,200 | 440,902 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 14,757,000 | 10,827,000 | 8,809,000 | 7,119,418 | 6,430,722 | 8,812,932 | 9,432,934 | 9,906,624 | 9,219,563 | 8,083,716 | 7,103,835 | 7,741,644 | 7,587,294 | 6,184,150 |
| total assets | 15,344,000 | 11,202,000 | 9,090,000 | 7,340,120 | 7,048,701 | 9,596,204 | 10,032,681 | 10,711,997 | 10,341,602 | 9,381,612 | 8,247,157 | 8,909,467 | 8,899,950 | 7,822,217 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 1,143,000 | 837,000 | 365,000 | 880,192 | 551,302 | 997,524 | 1,309,923 | 380,821 | 408,362 | 637,345 | 208,823 | 2,460,750 | 578,581 | 1,072,792 |
| Group/Directors Accounts | 4,381,000 | 1,507,000 | 450,000 | 149,081 | 0 | 2,780,633 | 2,827,331 | 2,760,097 | 2,760,097 | 2,760,097 | 3,149,683 | 3,291,871 | 3,966,419 | 2,524,341 |
| other short term finances | 0 | 0 | 0 | 239,343 | 883,186 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 3,013,000 | 2,547,000 | 2,383,000 | 2,478,523 | 2,545,367 | 3,091,030 | 3,369,427 | 2,789,868 | 3,092,649 | 2,248,200 | 1,826,966 | 645,702 | 1,670,108 | 1,093,821 |
| total current liabilities | 8,537,000 | 4,891,000 | 3,198,000 | 3,747,139 | 3,979,855 | 6,869,187 | 7,506,681 | 5,930,786 | 6,261,108 | 5,645,642 | 5,185,472 | 6,398,323 | 6,215,108 | 4,690,954 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 37,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10,288 |
| total long term liabilities | 37,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10,288 |
| total liabilities | 8,574,000 | 4,891,000 | 3,198,000 | 3,747,139 | 3,979,855 | 6,869,187 | 7,506,681 | 5,930,786 | 6,261,108 | 5,645,642 | 5,185,472 | 6,398,323 | 6,215,108 | 4,701,242 |
| net assets | 6,770,000 | 6,311,000 | 5,892,000 | 3,592,981 | 3,068,846 | 2,727,017 | 2,526,000 | 4,781,211 | 4,080,494 | 3,735,970 | 3,061,685 | 2,511,144 | 2,684,842 | 3,120,975 |
| total shareholders funds | 6,770,000 | 6,311,000 | 5,892,000 | 3,592,981 | 3,068,846 | 2,727,017 | 2,526,000 | 4,781,211 | 4,080,494 | 3,735,970 | 3,061,685 | 2,511,144 | 2,684,842 | 3,120,975 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 583,000 | 520,000 | 2,865,000 | 709,606 | -557,445 | -1,385 | ||||||||
| Depreciation | 369,000 | 160,000 | 0 | 660,685 | 292,356 | 396,759 | 375,242 | 449,285 | 453,528 | 513,975 | 506,571 | 498,544 | 490,559 | 485,511 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -122,000 | -99,000 | -567,000 | -185,470 | -881 | -175,036 | -177,815 | -179,891 | -100,523 | -179,706 | -196,661 | 50,182 | 123,908 | 64,480 |
| Stock | 280,000 | 161,000 | -195,541 | -20,952 | -923,183 | -440,318 | 96,093 | -1,211,909 | 254,789 | -751,691 | -719,507 | 517,797 | 698,351 | 3,393,071 |
| Debtors | 3,726,000 | 1,864,000 | 1,925,866 | 653,682 | -126,807 | 663,259 | 256,700 | -150,954 | 546,104 | 1,481,888 | 68,845 | -665,255 | 875,495 | 2,350,177 |
| Creditors | 306,000 | 472,000 | -515,192 | 328,890 | -446,222 | -312,399 | 929,102 | -27,541 | -228,983 | 428,522 | -2,251,927 | 1,882,169 | -494,211 | 1,072,792 |
| Accruals and Deferred Income | 466,000 | 164,000 | -95,523 | -66,844 | -545,663 | -278,397 | 579,559 | -302,781 | 844,449 | 421,234 | 1,181,264 | -1,024,406 | 576,287 | 1,093,821 |
| Deferred Taxes & Provisions | 37,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10,288 | 10,288 |
| Cash flow from operations | -2,367,000 | -808,000 | -43,040 | 814,137 | -1,445,036 | -3,017,741 | ||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 2,874,000 | 1,057,000 | 300,919 | 149,081 | -2,780,633 | -46,698 | 67,234 | 0 | 0 | -389,586 | -142,188 | -674,548 | 1,442,078 | 2,524,341 |
| Other Short Term Loans | 0 | 0 | -239,343 | -643,843 | 883,186 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | -2,000 | -2,000 | 1,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2,596 | -1,567 |
| cash flow from financing | 2,872,000 | 1,055,000 | 62,595 | -494,763 | -1,897,447 | -46,698 | 67,234 | 0 | 0 | -389,586 | -142,188 | -673,147 | 1,439,482 | 5,582,221 |
| cash and cash equivalents | ||||||||||||||
| cash | -76,000 | -7,000 | -40,743 | 55,966 | -1,332,220 | -842,943 | -826,483 | 2,049,924 | 334,954 | 249,684 | 12,853 | 301,808 | -170,702 | 440,902 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -76,000 | -7,000 | -40,743 | 55,966 | -1,332,220 | -842,943 | -826,483 | 2,049,924 | 334,954 | 249,684 | 12,853 | 301,808 | -170,702 | 440,902 |
P&L
December 2022turnover
11.8m
+14%
operating profit
583k
+12%
gross margin
35.7%
+11.74%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
6.8m
+0.07%
total assets
15.3m
+0.37%
cash
150k
-0.34%
net assets
Total assets minus all liabilities
Similar Companies
aquilant endoscopy limited company details
company number
03402556
Type
Private limited with Share Capital
industry
47749 - Retail sale of medical and orthopaedic goods (other than hearing aids) n.e.c., in specialised stores
incorporation date
July 1997
age
27
accounts
Full Accounts
ultimate parent company
previous names
imotech medical limited (October 2014)
endoscopy uk limited (February 2010)
incorporated
UK
address
aquilant house, unit b1-b2 bond close, basingstoke, RG24 8PZ
last accounts submitted
December 2022
aquilant endoscopy limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 10 charges/mortgages relating to aquilant endoscopy limited. Currently there are 0 open charges and 10 have been satisfied in the past.
aquilant endoscopy limited Companies House Filings - See Documents
| date | description | view/download |
|---|
